Company profile: Elucida Oncology
1.1 - Company Overview
Company description
- Provider of targeted C'Dot Drug Conjugates (CDCs) for patients with primary solid tumor and metastatic cancer. Ultra-small CDC nanoparticles penetrate tumors, carry high drug payloads, and clear rapidly via kidneys (Target or Clear) to reduce systemic exposure and off-target toxicity. Pipeline includes ELU001, a CDC targeting folate receptor alpha in clinical trials; ELU002; and surface chemistry for toxic payloads and radionuclides.
Products and services
- Target or Clear™: Proprietary property enabling effective tumor targeting and kidney-mediated clearance in CDCs, reducing non-specific organ accumulation and systemic exposure
- C'Dot Drug Conjugates (CDCs): Ultra-small nano-scale nanoparticles deeply infiltrate solid tumors and deliver high drug payloads, with rapid renal clearance to minimize systemic exposure and off-target toxicity
- ELU001: Clinical-stage CDC targeting solid tumors overexpressing folate receptor alpha, leveraging ultra-small particle architecture for deep tumor penetration and kidney clearance.
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Elucida Oncology
Crossject
HQ: France
Website
- Description: Provider of needle-free drug self-injection solutions, manufacturing and marketing ZENEO, a needle-free auto-injector enabling self-administration through the skin in less than a tenth of a second. Offers core needle-free technology and conducts R&D on self-injection systems, with seven products under development primarily for emergency situations and improving emergency medicine administration.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Crossject company profile →
scPharmaceuticals
HQ: United States
Website
- Description: Provider of biopharmaceutical products for subcutaneous delivery, including FUROSCIX, a furosemide injection for subcutaneous use to treat congestion due to fluid overload in adult patients with heart failure, and an investigational subcutaneous ceftriaxone delivery system for outpatient antibiotic therapy. Offers clinical trials, supports investigator-sponsored studies, educational grants, and medical information services.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full scPharmaceuticals company profile →
Xeris Biopharma
HQ: United States
Website
- Description: Provider of pharmaceutical therapies in endocrinology, neurology, and gastroenterology, including Gvoke and Ogluo ready-to-use glucagon injections for severe hypoglycemia; Keveyis, the first FDA-approved treatment for Primary Periodic Paralysis; Recorlev for endogenous Cushing's syndrome; and levothyroxine for hypothyroidism. Ogluo is marketed in the UK/EU under an exclusive agreement with Tetris Pharma.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Xeris Biopharma company profile →
Elektrofi
HQ: United States
Website
- Description: Provider of a microparticle platform (Hypercon) enabling low-volume, stable, hyper-concentrated biologic formulations for subcutaneous delivery, alongside formulation development services—covering process development, formulation, analytics, and innovation—and partnership programs with pharmaceutical companies to develop and commercialize subcutaneous biologic therapies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Elektrofi company profile →
MedinCell
HQ: France
Website
- Description: Provider of injectable slow-release drug expertise.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full MedinCell company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Elucida Oncology
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Elucida Oncology
2.2 - Growth funds investing in similar companies to Elucida Oncology
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Elucida Oncology
4.2 - Public trading comparable groups for Elucida Oncology
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →